Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors

Brigatinib produced responses in 23% of all tumors in patients with NF2 -related tumors (schwannomas, meningiomas, and ependymomas), with hearing improvement in approximately one third of patients.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2024-06, Vol.390 (24), p.2284-2294
Hauptverfasser:	Plotkin, Scott R., Yohay, Kaleb H., Nghiemphu, Phioanh L., Dinh, Christine T., Babovic-Vuksanovic, Dusica, Merker, Vanessa L., Bakker, Annette, Fell, Geoffrey, Trippa, Lorenzo, Blakeley, Jaishri O.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Medicine Baskets Brain cancer Brain Tumor Cancer Chemotherapy Childhood Cancer Childhood Diseases Design Drug dosages Enrollments Genetics Hematology Hypotheses Kinases Magnetic resonance imaging Meningioma Neurofibromatosis Neurofibromatosis 2 Neurology Neurosurgery Oncology Pain Patients Pediatrics Pediatrics General Quality of life Questionnaires Schwann cells Surgical outcomes Teenagers Treatments in Oncology Tumors Vestibular system Volumetric analysis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Brigatinib produced responses in 23% of all tumors in patients with NF2 -related tumors (schwannomas, meningiomas, and ependymomas), with hearing improvement in approximately one third of patients.
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa2400985